Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Drug Discovery Today

02:39 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Drug Discovery Today" found in our extensive news archives from over 250 global news sources.

More Information about Drug Discovery Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Drug Discovery Today for you to read. Along with our medical data and news we also list Drug Discovery Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of Drug Discovery Today Companies for you to search.

Showing News Articles 1–25 of 136 from Drug Discovery Today

Wednesday 19th September 2018

The Current issue of “The view from here” is concerned with Drug Delivery

The topic of this month’s newsletter from Drug Discovery Today is “Drug Delivery”.

Saturday 15th September 2018

Dangers of Tattoos - Even the New ECHA Proposals are Not Enough to Guarantee Safe Inks

Tattoos have definitely become mainstream, but possible dangers from tattoo inks include bacterial contamination, allergies, toxic effects and eventually the risk of cancer. Two in three people report side-effects after getting a tattoo. Even the new proposals developed by the European Chemical Agency (ECHA) are insufficient to guarantee safe inks without risk of toxicity and cancerogenicity. At t...

Friday 14th September 2018

UK set to be global leader in providing large-scale industrial access to Cryo-EM for drug discovery thanks to new collaboration

Thermo Fisher Scientific and Diamond Light Source are creating a step change for life sciences sector, a one-stop shop for structural biology and one of largest cryo-EM sites in the world.

Tuesday 11th September 2018

The Current issue of “The view from here” is concerned with Drug Delivery.

The topic of this month’s newsletter from Drug Discovery Today is “Drug Delivery”.

Sunday 2nd September 2018

MedPharm appoint Dr Jon Lenn and Dr Haydn Sinclair to Senior Scientific and Quality positions

Leading topical and transdermal delivery specialist MedPharm Ltd have announced the appointments of Dr Jon Lenn to the position of Chief Technology Officer (CTO) and Dr Haydn Sinclair to the role of Vice President of Pharmaceutical Quality with Global Responsibilities.

Saturday 1st September 2018

Novel therapeutic strategy for blood vessel related disorders, such as cancer and retinopathy - Important international recognition for Peter Carmeliet

Blood vessels sustain health and proper functioning of our body. A multi-disciplinary team of scientists, led by prof. Peter Carmeliet (VIB-KU Leuven Center for Cancer Biology) has made several breakthrough discoveries concerning the metabolism of the individual building blocks of blood vessels - the so-called endothelial cells. They identified three key proteins that determine how blood vessels g...

Wednesday 22nd August 2018

Leaf Expression Systems promises rich harvest for drug industry

Leaf Expression Systems, a contract biopharmaceutical development business specialising in plant-based expression of proteins, metabolites and complex natural products, announced today announced that its multi-million pound purpose-built facility on the Norwich Research Park is now fully operational amidst growing interest worldwide in its potentially game-changing plant transient expression techn...

Thursday 16th August 2018

Health leaders reveal ten most important medicines in NHS history

Antipsychotics, breast cancer drug, oral contraceptives and MMR vaccine make the top ten

Wednesday 15th August 2018

Sygnature Discovery announces ambitious expansion plan with addition of Alderley Park facility

Sygnature Discovery, a leading independent provider of integrated drug discovery and pre-clinical services and expertise, has today announced the next stage in its ambitious expansion plans with the addition of a new facility located at Alderley Park in Cheshire.

Friday 10th August 2018

The Current issue of “The view from here” is concerned with Models

The topic of this month’s newsletter from Drug Discovery Today is “Models”

Tuesday 7th August 2018

Novel oral therapies could transform the standard-of-care for Diabetic Macular Edema (DME) and lead to prophylactic treatment

The current standard-of-care for millions of patients across the world with diabetic macular edema (DME) relies on invasive intravitreal injections or implants, both of which are associated with serious risks and side effects. An oral DME treatment could not only provide a less intrusive and safer choice but could also pave the way for prophylactic treatment.

Thursday 2nd August 2018

Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells?

The therapeutic use of mesenchymal stem cells or MSCs was first investigated in humans in 1995, generating a great deal of early enthusiasm about their promise as easily manufactured allogeneic cellular medicines. Since 1995, MSCs have become one of the most clinically studied experimental cell therapy platforms in the world. After more than 20 years of MSC clinical research, which has not yet res...

Thursday 26th July 2018

New system can identify drugs to target ‘undruggable’ enzymes critical in many diseases

A new drug discovery system allows scientists to specifically target members of an important family of enzymes, called phosphatases, which were previously considered mostly “undruggable”.

Friday 20th July 2018

OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes

EpiSwitch™ biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 EpiSwitch™ biomarkers have been shown to offer prognostic stratifications in lymphoma patients Data presented at the ASH Summit on Emerging Immunotherapies for Hematologic Diseases on 13 July 2018, in Washington DC

Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)

Scientists at the University of Birmingham, UK, are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).

Monday 16th July 2018

The Current issue of “The view from here” is concerned with Novel Targets.

The topic of this month’s newsletter from Drug Discovery Today is “Novel Targets”.

Friday 13th July 2018

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.$133 Million Deal Adds European Early Development Center of Excellence to Global Network

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug develo...

Wednesday 11th July 2018

Cancer Models Platform is eliminating barriers for researchers in drug discovery

Cambridge (UK) tech start-up, Repositive, has introduced new features to its Cancer Models Platform, responding to feedback from the platform’s growing user base. The platform provides oncology researchers with a holistic, searchable, comparable view of existing cancer models, whilst providing Contract Research Organisations (CROs) - the providers of the cancer models - with a tool to market, ma...

Advanced in vitro methodologies demonstrate new paradigms for toxicological testing

Scientists from Philip Morris International (PMI) have presented details of a series of advanced techniques for the in vitro toxicological assessment of complex mixtures. For the scientific assessment of heated tobacco and e-cigarette aerosols, PMI has developed and tested methodologies using human cells grown in three-dimensional cultures, networks-based systems toxicological analysis, and organ-...

Friday 22nd June 2018

The Current issue of “The view from here” is concerned with Therapeutics

The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”

Thursday 14th June 2018

NHSA opens up £45bn Commonwealth life sciences economies to North

THE Northern Health Science Alliance has signed a memorandum of understanding (MOU) with Life Sciences Queensland Limited (LSQ) in Australia and another MOU with SCAN Health and World Health Innovation (WIN) in Canada to open the door to working across the Commonwealth countries.

Friday 8th June 2018

University of Huddersfield launches Centre for Pharmaceutical Policy and Practice Research

The pharmacy world has seen, and will continue to see, many advancements that will affect the industry and the way a pharmacy conducts its business. Now, a new research centre at the University of Huddersfield, will strive to ensure the industry is armed with the latest research methods and advice on policy and best practice.

The Current issue of “The view from here” is concerned with Allosterism in Drug Discovery.

The topic of this month’s newsletter from Drug Discovery Today is “Allosterism in Drug Discovery”.

Tuesday 5th June 2018

UK Institute to harness disruptive technology to transform drug discovery

Business Secretary Greg Clark today announced funding for a series of ambitious technology projects that will transform the way medicines are discovered, enabling the pharmaceutical industry to develop groundbreaking drugs faster, cheaper and better than ever before. The projects are the first wave of major initiatives for the £103m Rosalind Franklin Institute, that was launched today at the Har...

New research hub tackles the spread of new diseases

The Centre for Process Innovation (CPI), the UK’s technology innovation provider for process manufacturing, has announced its involvement in the development of a new research hub aimed at delivering high-quality vaccines at low cost, with aims of preventing outbreaks of diseases such as Zika and Ebola.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks